{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-017280","form_type":"8-K","ticker":"PASG","cik":"0001787297","company_name":"Passage BIO, Inc.","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.117752+00:00","generated_at":"2026-06-21T23:26:35.981080+00:00","sec_items":["2.02","5.02","7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Passage Bio reports Q3 net loss $26.7M; cuts workforce 23%, halts Krabbe program","bullets":["Net loss of $26.7M ($0.49 per share) vs $46.9M in Q3 2021; R&D expenses fell to $15.4M.","Cash $213.8M as of Sept 30, 2022; runway extended into first half 2025 via restructuring.","Workforce reduced ~23%; stop development of PBKR03 for Krabbe disease, explore strategic alternatives.","First patient dosed in Cohort 4 (high dose, early infantile) of Imagine-1 GM1 trial; data from Cohorts 2&3 expected Dec 2022.","First patient dosed in upliFT-D trial for frontotemporal dementia; William Chou appointed CEO in October."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-017280","json":"https://secwatch.observer/filing/0001558370-22-017280.json","markdown":"https://secwatch.observer/filing/0001558370-22-017280.md","text":"https://secwatch.observer/filing/0001558370-22-017280.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787297/000155837022017280/0001558370-22-017280-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787297/000155837022017280/pasg-20221108x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T23:26:35.981080+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"86d49f4cb889e7b473eb21bc876bdebcbe64a488","claim":"Passage BIO, Inc. reported the third quarter ended September 30, 2022 results: net income Net loss was $26.7 million, or a net loss of $0.49 per basic and diluted share, EPS a net loss of $0.49 per basic and diluted share.","evidence_excerpt":"Passage Bio Reports Third Quarter 2022 Financial Results And Provides Business Updates","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1787297/000155837022017280/0001558370-22-017280-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Net income","value":"Net loss was $26.7 million, or a net loss of $0.49 per basic and diluted share"},{"label":"EPS","value":"a net loss of $0.49 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"cd66d7796b","claim":"Maxine Gowen resigned as Interim Executive Chairwoman at Passage BIO, Inc..","evidence_excerpt":"On November 8, 2022, the Company received the resignation of Maxine Gowen from her role as Interim Executive Chairwoman of the Board of Directors of the Company (the “Board”), effective as of November 10, 2022 (the “Effective Date”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1787297/000155837022017280/0001558370-22-017280-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Interim Executive Chairwoman"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}